CD133, but Not CD44, May Serve as a Novel Biomarker for Differential Diagnosis Between Basal Cell Carcinoma and Trichoblastomas

Yalan Bi, Xiaohua Shi, Dian Chen, Yi ZhaoClinical 2022 · DOI

Abstract

Our study expanded upon previous studies of CD133 and CD44 expressions in skin tumors, suggesting that CD133, but not CD44, may serve as a novel biomarker for differential diagnosis of BCC, although future studies using a larger number of patients are needed to justify it further.
BibTeX
@inproceedings{bi2022cd,
  author = {Yalan Bi and Xiaohua Shi and Dian Chen and Yi Zhao},
  title = {{CD133, but Not CD44, May Serve as a Novel Biomarker for Differential Diagnosis Between Basal Cell Carcinoma and Trichoblastomas}},
  booktitle = {Clinical},
  year = {2022},
  doi = {10.2147/ccid.s373331},
}

Loading related content...

Figure